NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

Abstract

There is an urgent need for a safe and protective vaccine to control the global spread of SARS-CoV-2 and prevent COVID-19. Here, we report the immunogenicity and protective efficacy of a SARS-CoV-2 subunit vaccine (NVX-CoV2373) produced from the full-length SARS-CoV-2 spike (S) glycoprotein stabilized in the prefusion conformation. Cynomolgus macaques (Macaca fascicularis) immunized with NVX-CoV2373 and the saponin-based Matrix-M™ adjuvant induced anti-S antibody that was neutralizing and blocked binding to the human angiotensin-converting enzyme 2 (hACE2) receptor. Following intranasal and intratracheal challenge with SARS-CoV-2, immunized macaques were protected against upper and lower infection and pulmonary disease. These results support ongoing phase 1/2 clinical studies of the safety and immunogenicity of NVX-CoV2327 vaccine (NCT04368988).

Keywords

ImmunogenicityVirologyAdjuvantMedicineNeutralizing antibodySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Nasal administrationAntibodyImmunologyCoronavirus disease 2019 (COVID-19)BiologyVirusInfectious disease (medical specialty)DiseasePathology

Affiliated Institutions

Related Publications

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech , Gary Albert , Iksung Cho +26 more

At 35 days, NVX-CoV2373 appeared to be safe, and it elicited immune responses that exceeded levels in Covid-19 convalescent serum. The Matrix-M1 adjuvant induced CD4+ T-cell res...

2020 New England Journal of Medicine 1219 citations

Antigenic and Immunogenic Characterization of Recombinant Baculovirus-Expressed Severe Acute Respiratory Syndrome Coronavirus Spike Protein: Implication for Vaccine Design

Yuxian He , Jingjing Li , Susanne Heck +2 more

ABSTRACT The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus (SARS-CoV) mediates the receptor interaction and immune recognition and is considered a majo...

2006 Journal of Virology 135 citations

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Kizzmekia S. Corbett , Barbara J. Flynn , Kathryn E. Foulds +71 more

Vaccination of nonhuman primates with mRNA-1273 induced robust SARS-CoV-2 neutralizing activity, rapid protection in the upper and lower airways, and no pathologic changes in th...

2020 New England Journal of Medicine 1134 citations

Antigenic Cross‐Reactivity between Severe Acute Respiratory Syndrome–Associated Coronavirus and Human Coronaviruses 229E and OC43

Chi‐Ming Che , Li‐wen Qiu , Zhiyong Liao +7 more

Cross-reactivity between antibodies to different human coronaviruses (HCoVs) has not been systematically studied. By use of Western blot analysis, indirect immunofluorescence as...

2005 The Journal of Infectious Diseases 180 citations

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Evan J. Anderson , Nadine Rouphael , Alicia T. Widge +34 more

In this small study involving older adults, adverse events associated with the mRNA-1273 vaccine were mainly mild or moderate. The 100-μg dose induced higher binding- and neutra...

2020 New England Journal of Medicine 1581 citations

Publication Info

Year: 2020
Type: article
Volume: 38
Issue: 50
Pages: 7892-7896
Citations: 238
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

238

OpenAlex

Cite This

APA Style

                            
                                
                                    Mimi Guebre‐Xabier, 
                                
                                    Nita Patel, 
                                
                                    Jing-Hui Tian
                                
                                et al.
                            
                            (2020). 
                            NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. 
                            Vaccine
                            , 38
                            (50)
                            , 7892-7896.
                            https://doi.org/10.1016/j.vaccine.2020.10.064
                        

Identifiers

DOI: 10.1016/j.vaccine.2020.10.064